Maze Therapeutics (MAZE) Interest Expenses (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Interest Expenses data on file, last reported at -$3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses changed N/A year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at -$3.7 million (changed N/A YoY), and the FY2025 full-year result was $163.5 million, up 85.51% from the prior year.
• Interest Expenses fell to -$3.7 million in Q1 2026, from $112.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $112.0 million in Q4 2025 to a low of -$3.7 million in Q1 2026.
• A 3-year average of $65.5 million and a median of $88.1 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 27.11% in 2025, while the deepest fall reached 27.11% in 2025.
• Tracing MAZE's Interest Expenses over 3 years: stood at $88.1 million in 2024, then grew by 27.11% to $112.0 million in 2025, then slumped by 103.34% to -$3.7 million in 2026.
• Business Quant data shows MAZE's Interest Expenses at -$3.7 million in Q1 2026, $112.0 million in Q4 2025, and $88.1 million in Q4 2024.